JP5331817B2 - 新規な非選択的ソマトスタチン類似体 - Google Patents

新規な非選択的ソマトスタチン類似体 Download PDF

Info

Publication number
JP5331817B2
JP5331817B2 JP2010535349A JP2010535349A JP5331817B2 JP 5331817 B2 JP5331817 B2 JP 5331817B2 JP 2010535349 A JP2010535349 A JP 2010535349A JP 2010535349 A JP2010535349 A JP 2010535349A JP 5331817 B2 JP5331817 B2 JP 5331817B2
Authority
JP
Japan
Prior art keywords
phe
compound according
group
tyr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010535349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505345A5 (enExample
JP2011505345A (ja
Inventor
ヴィタリー アンドレア
ピノーリ マッシモ
マスカーニ パオロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20072266 external-priority patent/ITMI20072266A1/it
Priority claimed from EP07425778A external-priority patent/EP2067786A1/en
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of JP2011505345A publication Critical patent/JP2011505345A/ja
Publication of JP2011505345A5 publication Critical patent/JP2011505345A5/ja
Application granted granted Critical
Publication of JP5331817B2 publication Critical patent/JP5331817B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2010535349A 2007-12-03 2008-11-24 新規な非選択的ソマトスタチン類似体 Active JP5331817B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI20072266 ITMI20072266A1 (it) 2007-12-03 2007-12-03 Nuovi analoghi non selettivi di somatostatina
ITMI2007A002266 2007-12-03
EP07425778A EP2067786A1 (en) 2007-12-07 2007-12-07 Novel non selective analogs of somatostatin
EP07425778.3 2007-12-07
PCT/EP2008/066081 WO2009071460A2 (en) 2007-12-03 2008-11-24 New non-selective somatostatin analogues

Publications (3)

Publication Number Publication Date
JP2011505345A JP2011505345A (ja) 2011-02-24
JP2011505345A5 JP2011505345A5 (enExample) 2011-08-04
JP5331817B2 true JP5331817B2 (ja) 2013-10-30

Family

ID=40667736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535349A Active JP5331817B2 (ja) 2007-12-03 2008-11-24 新規な非選択的ソマトスタチン類似体

Country Status (15)

Country Link
US (1) US8937152B2 (enExample)
EP (1) EP2225271B1 (enExample)
JP (1) JP5331817B2 (enExample)
KR (1) KR101500528B1 (enExample)
CN (1) CN101883785B (enExample)
BR (1) BRPI0818978B8 (enExample)
CA (1) CA2702940C (enExample)
CY (1) CY1114490T1 (enExample)
DK (1) DK2225271T3 (enExample)
ES (1) ES2431573T3 (enExample)
HR (1) HRP20130948T1 (enExample)
PL (1) PL2225271T3 (enExample)
PT (1) PT2225271E (enExample)
SI (1) SI2225271T1 (enExample)
WO (1) WO2009071460A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
CN101883785B (zh) * 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2013032012A1 (ja) * 2011-09-04 2013-03-07 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
DK3007704T3 (da) * 2013-06-13 2021-03-29 Antisense Therapeutics Ltd Kombinationsterapi til akromegali
CN103467575B (zh) * 2013-08-22 2016-03-02 深圳翰宇药业股份有限公司 一种帕西瑞肽的制备方法
CN103641894B (zh) * 2013-12-06 2015-10-28 深圳翰宇药业股份有限公司 一种治疗库欣病的多肽药物的制备方法
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
CN104447962B (zh) * 2014-12-29 2018-07-17 成都圣诺生物科技股份有限公司 一种合成帕瑞肽的方法
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2020064693A1 (en) * 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
GB201816637D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd Selective somatostatin receptor agonists
US20240165282A1 (en) * 2021-03-04 2024-05-23 Starget Pharma Ltd. Conformational constrained somatostatin receptor 3 peptide ligands and their conjugates and uses thereof
IT202100032615A1 (it) 2021-12-24 2023-06-24 Italfarmaco Spa Uso di un agonista della somatostatina nel trattamento di tumori che esprimono SSTR3
CN119708199A (zh) * 2023-09-27 2025-03-28 钱杭江医药科技(嘉兴)有限公司 生长抑素肽类类似物、螯合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US6365380B2 (en) 2000-02-23 2002-04-02 Pcbu Services, Inc. Method for stereoselectively inverting a chiral center of a chemical compound using an enzyme and a metal catalyst
AU2003212430B2 (en) * 2002-03-12 2006-05-25 Noxell Corporation Cosmetic composition comprising double coated pigment
GB0206415D0 (en) 2002-03-19 2002-05-01 Glaxo Group Ltd Deracemisation of amines
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
US20060270730A1 (en) * 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
GB0318682D0 (en) 2003-08-08 2003-09-10 Novartis Ag Organic compounds
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
AU2004294269A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Biomarkers for the efficacy of somatostatin analogue treatment
ITFI20040057A1 (it) * 2004-03-10 2004-06-10 Mauro Giuntini Analoghi della somatostatina
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US7824663B2 (en) * 2005-03-10 2010-11-02 Kokyu Alcohol Kogyo Co., Ltd. Lip gloss composition
SI1787658T1 (sl) * 2005-11-10 2012-07-31 Chemi Spa Formulacije z trajnim sproščanjem somatostatin analognih inhibitorjev rastnega hormona
CN101883785B (zh) * 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物

Also Published As

Publication number Publication date
PL2225271T3 (pl) 2013-12-31
CA2702940A1 (en) 2009-06-11
US20100323964A1 (en) 2010-12-23
CA2702940C (en) 2016-09-13
CN101883785B (zh) 2014-01-15
BRPI0818978A2 (pt) 2016-05-03
BRPI0818978B1 (pt) 2019-09-10
CN101883785A (zh) 2010-11-10
WO2009071460A2 (en) 2009-06-11
ES2431573T3 (es) 2013-11-27
KR101500528B1 (ko) 2015-03-09
EP2225271B1 (en) 2013-07-31
DK2225271T3 (da) 2013-10-07
WO2009071460A3 (en) 2009-12-17
CY1114490T1 (el) 2016-10-05
EP2225271A2 (en) 2010-09-08
KR20100103464A (ko) 2010-09-27
SI2225271T1 (sl) 2013-10-30
JP2011505345A (ja) 2011-02-24
PT2225271E (pt) 2013-09-27
HRP20130948T1 (hr) 2013-11-08
US8937152B2 (en) 2015-01-20
BRPI0818978B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CN101883785B (zh) 新的非选择性生长抑素类似物
KR101169846B1 (ko) 시클릭 펩티드 ｃｘｃｒ４ 길항제
JP5254868B2 (ja) ソマトスタチン−ドーパミンキメラ類似体
US7541018B2 (en) Treatment process using somatostatin analogues
CN1189166A (zh) 抑生长素肽
CN112585157A (zh) 用于结合整联蛋白αvβ3的肽配体
JP2004339237A (ja) 治療効果のあるペプチド誘導体
JP2002518339A (ja) コンフォメーション的に拘束された主鎖環化ソマトスタチン類似体
CZ20033122A3 (cs) Chimérické somatostatin@dopaminové analogy
WO2010065572A1 (en) Sstr1-selective analogs
JP5908184B2 (ja) ソマトスタチン−ドーパミンのキメラ類似体
AU2004251866B2 (en) Pharmaceutical composition comprising cyclic somatostatin analogues
US20080132453A1 (en) Neuromedin B and somatostatin receptor agonists
EP2067786A1 (en) Novel non selective analogs of somatostatin
CN101563360A (zh) 肽-细胞毒性缀合物
ITMI20072266A1 (it) Nuovi analoghi non selettivi di somatostatina
CN1812997B (zh) 包含促生长素抑制素类似物的胃肠外药物组合物
EP4656654A1 (en) Somatostatin peptide analogue, chelate and use thereof
RS51950B (sr) Ciklični peptidi antagonisti cxcr4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130729

R150 Certificate of patent or registration of utility model

Ref document number: 5331817

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250